Stock analysts expect Elanco Animal Health Incorporated (NYSE: MOMENTUM – Get a rating) will post sales of $1.22 billion for the current fiscal quarter, Zacks reports. Five analysts have released earnings estimates for Elanco Animal Health. The highest sales estimate is $1.23 billion and the lowest is $1.21 billion. Elanco Animal Health reported sales of $1.24 billion in the same quarter last year, which would indicate a negative 1.6% year-over-year growth rate. The company is expected to release its next quarterly results before the market opens on Monday, January 1.
On average, analysts expect Elanco Animal Health to report annual revenue of $4.78 billion in the current fiscal year, with estimates ranging from $4.77 billion to $4.79 billion. dollars. For next year, analysts expect the company to post sales of $4.94 billion, with estimates ranging from $4.90 billion to $4.99 billion. Zacks sales calculations are an average average based on a survey of sell-side research companies that provide coverage for Elanco Animal Health.
Elanco Animal Health (NYSE: MOMENTUM – Get a rating) last announced its quarterly results on Thursday, February 24. The company reported earnings per share (EPS) of $0.21 for the quarter, beating the consensus estimate of $0.17 by $0.04. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. The company posted revenue of $1.11 billion in the quarter, versus a consensus estimate of $1.10 billion. In the same period a year earlier, the company had earned earnings per share of $0.12. The company’s revenue for the quarter decreased 2.3% compared to the same quarter last year.
Several research analysts have recently weighed in on ELAN shares. Barclays raised its price target on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a Monday, February 28 research report. Zacks Investment Research upgraded Elanco Animal Health from a “sell” rating to a “hold” rating in a Monday, February 28 research report. Four research analysts gave the stock a hold rating and six gave the company a buy rating. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Buy” and a consensus price target of $38.43.
In other Elanco Animal Health news, Director David Hoover acquired 5,000 shares of the company in a transaction dated Tuesday, March 1. The stock was purchased at an average cost of $28.66 per share, with a total value of $143,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Insiders of the company own 6.11% of the shares of the company.
Hedge funds and other institutional investors have recently changed their positions in the company. Clearstead Advisors LLC bought a new position in Elanco Animal Health during Q3 for $31,000. Herold Advisors Inc. bought a new position in Elanco Animal Health during the 3rd quarter at a value of $31,000. CKW Financial Group bought a new position in Elanco Animal Health during the 4th quarter at a value of $30,000. First Horizon Advisors Inc. bought a new position in Elanco Animal Health during Q3 for $36,000. Finally, Benjamin Edwards Inc. increased its stake in Elanco Animal Health by 157.1% during the 4th quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company worth $40,000 after acquiring an additional 872 shares during the period. Institutional investors hold 97.90% of the company’s shares.
Shares of Stock Elanco Animal Health traded down $0.01 during Tuesday trading hours, hitting $26.25. The company’s stock had a trading volume of 3,691,664 shares, compared to its average volume of 3,457,464. Elanco Animal Health has a 12-month low of $24.15 and a 12-month high of 37. $49. The stock has a 50-day moving average of $26.53 and a 200-day moving average of $28.68. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt ratio of 0.80.
About Elanco Animal Health (Get a rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets pet and farm animal products. It offers disease prevention products for companion animals, such as parasiticide products and vaccines that protect animals against worms, fleas and ticks under the brand names Seresto, Advantage, Advantix and Advocate; companion animal health therapies for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in dogs and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the Rumensin and Baytril brands.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily newsletter.